Cagrilintide (5mg)

 Structural Classification

Cagrilintide is a long-acting, acylated amylin analog designed to mimic and enhance the activity of human islet amyloid polypeptide (IAPP).

• Peptide length: 37 amino acids (amylin backbone)
• Class: Amylin receptor agonist
• Modifications:
  • Amino acid substitutions (reduce aggregation)
  • Lipidation (fatty acid conjugation) for albumin binding
  • C-terminal amidation

These modifications transform a naturally unstable hormone into a long-acting therapeutic peptide analog.

 Mechanism of Action

Cagrilintide acts primarily through amylin receptor complexes, which are formed by:

• Calcitonin receptor (CTR)
  • Receptor activity-modifying proteins (RAMPs)

Downstream Effects:

• Activation of central satiety pathways (area postrema, hypothalamus)
• Slowing of gastric emptying
• Reduction in postprandial glucagon secretion
• Modulation of energy intake signaling

Central Nervous System Effects

Cagrilintide strongly influences appetite regulation:

• Acts on area postrema (brainstem) → reduces hunger signaling
• Enhances meal termination signals
• Reduces food reward behavior

This differs from GLP-1 analogs slightly by:

• Having a more direct satiety signal
• Less reliance on insulin-mediated pathways

Pharmacokinetics (Research Data)

Key design goal: extend half-life vs native amylin

• Native amylin half-life: ~10–15 minutes
• Cagrilintide half-life: ~1 week (due to lipidation + albumin binding)

Mechanism of Extension:

• Fatty acid side chain → reversible albumin binding reservoir
• Reduced renal clearance
• Protection from enzymatic degradation